Different types of botulinum toxin in humans
Identifieur interne : 003D44 ( Main/Exploration ); précédent : 003D43; suivant : 003D45Different types of botulinum toxin in humans
Auteurs : Roberto Eleopra [Italie] ; Valeria Tugnoli [Italie] ; Rocco Quatrale [Italie] ; Ornella Rossetto [Italie] ; Cesare Montecucco [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-03.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Anti-Dyskinesia Agents (classification), Anti-Dyskinesia Agents (pharmacology), Bontoxilysin, Botulinum Toxins (classification), Botulinum Toxins (pharmacology), Electric Stimulation (methods), Evoked Potentials, Motor (drug effects), Evoked Potentials, Motor (radiation effects), Female, Human, Humans, Injections, Intramuscular (methods), Male, Middle Aged, Muscle, Skeletal (drug effects), Nervous system diseases, Time Factors, botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type F, diffusion, duration of action, electromyography.
- MESH :
- chemical , classification : Anti-Dyskinesia Agents, Botulinum Toxins.
- chemical , pharmacology : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug effects : Evoked Potentials, Motor, Muscle, Skeletal.
- methods : Electric Stimulation, Injections, Intramuscular.
- radiation effects : Evoked Potentials, Motor.
- Adult, Female, Humans, Male, Middle Aged, Time Factors.
Abstract
In humans, botulinum neurotoxin (BoNT) serotype A (BoNT/A) is a useful therapeutic tool, but different BoNT serotypes may be useful when a specific immune resistance related to BoNT/A is proved. BoNT serotype F (BoNT/F) was injected into human muscles but its effects are shorter compared to BoNT/A, whereas BoNT serotype B (BoNT/B) is effective in humans only if injected at very high doses. BoNT serotype C (BoNT/C) has a general profile of action similar to BoNT/A. Nevertheless, a comparison between these different BoNTs in human has not yet been reported. To establish the general profile of these different BoNTs in humans and the spread in near and untreated muscles we conducted an electrophysiological evaluation in 12 healthy volunteers by injecting BoNT/A (BOTOX 15MU), BoNT/B (NeuroBloc 1500MU), BoNT/F (15MU), BoNT/C (15MU) and a saline solution (placebo) in the abductor digiti minimi muscle (ADM) in a double‐blind manner. The compound muscle action potential (CMAP) amplitude variation, before and at 2, 4, 6 and 8 weeks after the injections, was evaluated in the ADM, the fourth dorsal interosseus, the first dorsal interosseus and the abductor pollicis brevis APB. We detected an earlier recovery for BoNT/F when compared to the other BoNTs. No significant differences in the local or distant BoNT spread was observed among the different serotypes. We conclude that in humans, BoNT/B and BoNT/C have a general profile similar to BoNT/A and as such these serotypes could be alternative therapies to BoNT/A. BoNT/F might be useful when only a short duration of neuromuscular blockade is required. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20010
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001335
- to stream Istex, to step Curation: 001335
- to stream Istex, to step Checkpoint: 002725
- to stream PubMed, to step Corpus: 003512
- to stream PubMed, to step Curation: 003512
- to stream PubMed, to step Checkpoint: 003491
- to stream Ncbi, to step Merge: 000D72
- to stream Ncbi, to step Curation: 000D72
- to stream Ncbi, to step Checkpoint: 000D72
- to stream Main, to step Merge: 005702
- to stream PascalFrancis, to step Corpus: 002239
- to stream PascalFrancis, to step Curation: 000A82
- to stream PascalFrancis, to step Checkpoint: 002178
- to stream Main, to step Merge: 005A16
- to stream Main, to step Curation: 003D44
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Different types of botulinum toxin in humans</title><author><name sortKey="Eleopra, Roberto" sort="Eleopra, Roberto" uniqKey="Eleopra R" first="Roberto" last="Eleopra">Roberto Eleopra</name></author><author><name sortKey="Tugnoli, Valeria" sort="Tugnoli, Valeria" uniqKey="Tugnoli V" first="Valeria" last="Tugnoli">Valeria Tugnoli</name></author><author><name sortKey="Quatrale, Rocco" sort="Quatrale, Rocco" uniqKey="Quatrale R" first="Rocco" last="Quatrale">Rocco Quatrale</name></author><author><name sortKey="Rossetto, Ornella" sort="Rossetto, Ornella" uniqKey="Rossetto O" first="Ornella" last="Rossetto">Ornella Rossetto</name></author><author><name sortKey="Montecucco, Cesare" sort="Montecucco, Cesare" uniqKey="Montecucco C" first="Cesare" last="Montecucco">Cesare Montecucco</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C9E9953F6DB58F8D952E9413201E9C59C241082D</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20010</idno><idno type="url">https://api.istex.fr/document/C9E9953F6DB58F8D952E9413201E9C59C241082D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001335</idno><idno type="wicri:Area/Istex/Curation">001335</idno><idno type="wicri:Area/Istex/Checkpoint">002725</idno><idno type="wicri:doubleKey">0885-3185:2004:Eleopra R:different:types:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15027055</idno><idno type="wicri:Area/PubMed/Corpus">003512</idno><idno type="wicri:Area/PubMed/Curation">003512</idno><idno type="wicri:Area/PubMed/Checkpoint">003491</idno><idno type="wicri:Area/Ncbi/Merge">000D72</idno><idno type="wicri:Area/Ncbi/Curation">000D72</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D72</idno><idno type="wicri:doubleKey">0885-3185:2004:Eleopra R:different:types:of</idno><idno type="wicri:Area/Main/Merge">005702</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0228811</idno><idno type="wicri:Area/PascalFrancis/Corpus">002239</idno><idno type="wicri:Area/PascalFrancis/Curation">000A82</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002178</idno><idno type="wicri:doubleKey">0885-3185:2004:Eleopra R:different:types:of</idno><idno type="wicri:Area/Main/Merge">005A16</idno><idno type="wicri:Area/Main/Curation">003D44</idno><idno type="wicri:Area/Main/Exploration">003D44</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Different types of botulinum toxin in humans</title><author><name sortKey="Eleopra, Roberto" sort="Eleopra, Roberto" uniqKey="Eleopra R" first="Roberto" last="Eleopra">Roberto Eleopra</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Clinical Neurosciences, S. Anna University Hospital, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Tugnoli, Valeria" sort="Tugnoli, Valeria" uniqKey="Tugnoli V" first="Valeria" last="Tugnoli">Valeria Tugnoli</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Clinical Neurosciences, S. Anna University Hospital, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Quatrale, Rocco" sort="Quatrale, Rocco" uniqKey="Quatrale R" first="Rocco" last="Quatrale">Rocco Quatrale</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Clinical Neurosciences, S. Anna University Hospital, Ferrara</wicri:regionArea><wicri:noRegion>Ferrara</wicri:noRegion></affiliation></author><author><name sortKey="Rossetto, Ornella" sort="Rossetto, Ornella" uniqKey="Rossetto O" first="Ornella" last="Rossetto">Ornella Rossetto</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Biomedical Sciences Department, University of Padua, Padua</wicri:regionArea><wicri:noRegion>Padua</wicri:noRegion></affiliation></author><author><name sortKey="Montecucco, Cesare" sort="Montecucco, Cesare" uniqKey="Montecucco C" first="Cesare" last="Montecucco">Cesare Montecucco</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Biomedical Sciences Department, University of Padua, Padua</wicri:regionArea><wicri:noRegion>Padua</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03">2004-03</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">S8</biblScope><biblScope unit="page" from="S53">S53</biblScope><biblScope unit="page" to="S59">S59</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C9E9953F6DB58F8D952E9413201E9C59C241082D</idno><idno type="DOI">10.1002/mds.20010</idno><idno type="ArticleID">MDS20010</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-Dyskinesia Agents (classification)</term><term>Anti-Dyskinesia Agents (pharmacology)</term><term>Bontoxilysin</term><term>Botulinum Toxins (classification)</term><term>Botulinum Toxins (pharmacology)</term><term>Electric Stimulation (methods)</term><term>Evoked Potentials, Motor (drug effects)</term><term>Evoked Potentials, Motor (radiation effects)</term><term>Female</term><term>Human</term><term>Humans</term><term>Injections, Intramuscular (methods)</term><term>Male</term><term>Middle Aged</term><term>Muscle, Skeletal (drug effects)</term><term>Nervous system diseases</term><term>Time Factors</term><term>botulinum toxin type A</term><term>botulinum toxin type B</term><term>botulinum toxin type C</term><term>botulinum toxin type F</term><term>diffusion</term><term>duration of action</term><term>electromyography</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Evoked Potentials, Motor</term><term>Muscle, Skeletal</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Electric Stimulation</term><term>Injections, Intramuscular</term></keywords><keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>Evoked Potentials, Motor</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term><term>Homme</term><term>Système nerveux pathologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In humans, botulinum neurotoxin (BoNT) serotype A (BoNT/A) is a useful therapeutic tool, but different BoNT serotypes may be useful when a specific immune resistance related to BoNT/A is proved. BoNT serotype F (BoNT/F) was injected into human muscles but its effects are shorter compared to BoNT/A, whereas BoNT serotype B (BoNT/B) is effective in humans only if injected at very high doses. BoNT serotype C (BoNT/C) has a general profile of action similar to BoNT/A. Nevertheless, a comparison between these different BoNTs in human has not yet been reported. To establish the general profile of these different BoNTs in humans and the spread in near and untreated muscles we conducted an electrophysiological evaluation in 12 healthy volunteers by injecting BoNT/A (BOTOX 15MU), BoNT/B (NeuroBloc 1500MU), BoNT/F (15MU), BoNT/C (15MU) and a saline solution (placebo) in the abductor digiti minimi muscle (ADM) in a double‐blind manner. The compound muscle action potential (CMAP) amplitude variation, before and at 2, 4, 6 and 8 weeks after the injections, was evaluated in the ADM, the fourth dorsal interosseus, the first dorsal interosseus and the abductor pollicis brevis APB. We detected an earlier recovery for BoNT/F when compared to the other BoNTs. No significant differences in the local or distant BoNT spread was observed among the different serotypes. We conclude that in humans, BoNT/B and BoNT/C have a general profile similar to BoNT/A and as such these serotypes could be alternative therapies to BoNT/A. BoNT/F might be useful when only a short duration of neuromuscular blockade is required. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Eleopra, Roberto" sort="Eleopra, Roberto" uniqKey="Eleopra R" first="Roberto" last="Eleopra">Roberto Eleopra</name></noRegion><name sortKey="Montecucco, Cesare" sort="Montecucco, Cesare" uniqKey="Montecucco C" first="Cesare" last="Montecucco">Cesare Montecucco</name><name sortKey="Quatrale, Rocco" sort="Quatrale, Rocco" uniqKey="Quatrale R" first="Rocco" last="Quatrale">Rocco Quatrale</name><name sortKey="Rossetto, Ornella" sort="Rossetto, Ornella" uniqKey="Rossetto O" first="Ornella" last="Rossetto">Ornella Rossetto</name><name sortKey="Tugnoli, Valeria" sort="Tugnoli, Valeria" uniqKey="Tugnoli V" first="Valeria" last="Tugnoli">Valeria Tugnoli</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C9E9953F6DB58F8D952E9413201E9C59C241082D
|texte= Different types of botulinum toxin in humans
}}
| This area was generated with Dilib version V0.6.23. |  |